The authors assessed the efficacy and safety of B cell maturation antigen (BCMA) and CD38 bispecific CAR-T cells in refractory multiple myeloma patients.
[Journal of Experimental & Clinical Cancer Research]
Sorry, but the selected Zotpress account can't be found.
